Tempest Therapeutics detailed its in vivo CAR T pipeline built around CD7-targeted mRNA delivery using lipid nanoparticles (CD7-tLNP). The company is positioning the platform to broaden CAR T reach while emphasizing scalable delivery as an alternative to ex vivo manufacturing. Tempest’s approach aims for efficient in vivo T-cell engagement using an mRNA/LNP format, which is intended to improve delivery efficiency and expand the number of T-cell subsets that can be reached. For oncology product development, the update adds another in vivo CAR T contender to a rapidly growing field, where scalable manufacturing and patient access have become as critical as clinical potency.